Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Multiple Sclerosis

Free Subscription 05.07.2021 2 Ann Neurol 1 Arch Phys Med Rehabil 2 BMC Neurol 1 Brain 1 J Clin Invest 1 J Neuroimmunol 4 J Neurol 1 J Neurol Neurosurg Psychiatry 3 J Neurol Sci 1 Lancet 3 Mult Scler 1 Nat Rev Neurol 2 Neurology 1 Proc Natl Acad Sci U S A 1 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. HAUSER SL
   Curing Multiple Sclerosis: How to Know When We're There?
   Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
   PubMed        
   
   
2. GELIBTER S, Pisa M, Croese T, Finardi A, et al
   Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
   Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
   PubMed         Abstract available
   
   

   
   Arch Phys Med Rehabil

3. GROMISCH ES, Neto LO, Turner AP
   What Biopsychosocial Factors Explain Self-Management Behaviors in Multiple Sclerosis? The Role of Demographics, Cognition, Personality, and Psychosocial and Physical Functioning.
   Arch Phys Med Rehabil. 2021 Jun 24. pii: S0003-9993(21)00455.
   PubMed         Abstract available
   
   

   
   BMC Neurol

4. EHTESHAM N, Rafie MZ, Mosallaei M
   The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis.
   BMC Neurol. 2021;21:246.
   PubMed         Abstract available
   
   
5. AMINI P, Almasi-Hashiani A, Sahraian MA, Najafi M, et al
   Multiple sclerosis projection in Tehran, Iran using Bayesian structural time series.
   BMC Neurol. 2021;21:235.
   PubMed         Abstract available
   
   

   
   Brain

6. BITTNER S, Oh J, Havrdova EK, Tintore M, et al
   The potential of serum neurofilament as biomarker for multiple sclerosis.
   Brain. 2021 Jun 28. pii: 6310737. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Clin Invest

7. GHEZZI L, Cantoni C, Pinget GV, Zhou Y, et al
   Targeting the gut to treat multiple sclerosis.
   J Clin Invest. 2021;131.
   PubMed         Abstract available
   
   

   
   J Neuroimmunol

8. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
   Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
   J Neuroimmunol. 2021;358:577636.
   PubMed         Abstract available
   
   

   
   J Neurol

9. SANKARI SE, Van Essche C, van Pesch V
   Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
   J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.
   PubMed        
   
   
10. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.
    PubMed        
    
    
11. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    PubMed         Abstract available
    
    
12. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    PubMed         Abstract available
    
    

    
    J Neurol Neurosurg Psychiatry

13. WANG C, Barton J, Kyle K, Ly L, et al
    Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.
    J Neurol Neurosurg Psychiatry. 2021 Jun 29. pii: jnnp-2021-326164.
    PubMed         Abstract available
    
    

    
    J Neurol Sci

14. WIJERATNE T, Grisold W, Carroll W
    World Brain Day 2021 campaign continue to gain the momentum; join us to stop multiple sclerosis.
    J Neurol Sci. 2021;427:117547.
    PubMed        
    
    
15. VAN DER HIELE K, van Gorp DAM, van Egmond EEA, Jongen PJ, et al
    Self-reported occupational functioning in persons with relapsing-remitting multiple sclerosis: Does personality matter?
    J Neurol Sci. 2021;427:117561.
    PubMed         Abstract available
    
    
16. JAKIMOVSKI D, Zivadinov R, Vaughn CB, Ozel O, et al
    Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis.
    J Neurol Sci. 2021;427:117552.
    PubMed         Abstract available
    
    

    
    Lancet

17. MCGINLEY MP, Cohen JA
    Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    Lancet. 2021 Jun 24. pii: S0140-6736(21)00244.
    PubMed         Abstract available
    
    

    
    Mult Scler

18. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
    Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
    Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
    PubMed         Abstract available
    
    
19. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
    Performance validity in outpatients with multiple sclerosis and cognitive complaints.
    Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
    PubMed         Abstract available
    
    
20. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
    Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
    PubMed         Abstract available
    
    

    
    Nat Rev Neurol

21. WOOD H
    TSPO levels in multiple sclerosis lesions reflect microglial density rather than activation state.
    Nat Rev Neurol. 2021 Jun 29. pii: 10.1038/s41582-021-00533.
    PubMed        
    
    

    
    Neurology

22. GRAY-RONCAL K, Fitzgerald K, Ryerson LZ, Charvet L, et al
    Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012362.
    PubMed         Abstract available
    
    
23. ROOS I, Leray E, Casey R, Horakova D, et al
    Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012354.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

24. COLOMBO E, Triolo D, Bassani C, Bedogni F, et al
    Dysregulated copper transport in multiple sclerosis may cause demyelination via astrocytes.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available
    
    

    
    Rev Neurol (Paris)

25. GUERY D, Marignier R, Durand-Dubief F, Lavie C, et al
    Clinical failure of natalizumab in multiple sclerosis: Specific causes and strategy.
    Rev Neurol (Paris). 2021 Jun 24. pii: S0035-3787(21)00583.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: